Katerina V Gurova

List of Publications by Year
in descending order

66	3,019	159585 30	168389 53
papers	citations	h-index	g-index

71	71	71	3625
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-ÎºB-dependent mechanism of p53 suppression in tumors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17448-17453.	7.1	257
2	New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncology, 2009, 5, 1685-1704.	2.4	211
3	Curaxins: Anticancer Compounds That Simultaneously Suppress NF-ÎºB and Activate p53 by Targeting FACT. Science Translational Medicine, 2011, 3, 95ra74.	12.4	199
4	Inflammation and p53: A Tale of Two Stresses. Genes and Cancer, 2011, 2, 503-516.	1.9	156
5	AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene, 2002, 21, 3532-3540.	5.9	132
6	Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Science Translational Medicine, 2015, 7, 312ra176.	12.4	120
7	Facilitates Chromatin Transcription Complex Is an â€œAcceleratorâ€•of Tumor Transformation and Potential Marker and Target of Aggressive Cancers. Cell Reports, 2013, 4, 159-173.	6.4	116
8	Small-Molecule Multidrug Resistanceâ€“Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma. Cancer Research, 2009, 69, 6573-6580.	0.9	100
9	p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism. Cancer Research, 2004, 64, 1951-1958.	0.9	95
10	Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells. Oncotarget, 2011, 2, 783-796.	1.8	89
11	Structure and function of the histone chaperone FACT â€“ Resolving FACTual issues. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2018, 1861, 892-904.	1.9	84
12	FACT is a sensor of DNA torsional stress in eukaryotic cells. Nucleic Acids Research, 2017, 45, gkw1366.	14.5	75
13	Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models. Cancer Research, 2016, 76, 2432-2442.	0.9	62
14	Structure and Regulation of the Mouse ing1 Gene. Journal of Biological Chemistry, 1999, 274, 32172-32181.	3.4	60
15	Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Research, 2018, 78, 1431-1443.	0.9	60
16	p53 Determines Multidrug Sensitivity of Childhood Neuroblastoma. Cancer Research, 2007, 67, 10351-10360.	0.9	57
17	Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-ÎºB, and Cell-Cycle Progression in Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2014, 13, 2203-2214.	4.1	57
18	Anti-malaria drug blocks proteotoxic stress response: Anti-cancer implications. Cell Cycle, 2009, 8, 3960-3970.	2.6	52

#	Article	IF	Citations
19	Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2/neu Transgenic Mice. Cancer Prevention Research, 2012, 5, 1025-1035.	1.5	52
20	Complex mutual regulation of facilitates chromatin transcription (FACT) subunits on both mRNA and protein levels in human cells. Cell Cycle, 2013, 12, 2423-2434.	2.6	48
21	Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget, 2014, 5, 11038-11053.	1.8	48
22	Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins. Science Advances, 2018, 4, eaav2131.	10.3	47
23	Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene, 2002, 21, 153-157.	5.9	45
24	Paradoxical role of apoptosis in tumor progression. Journal of Cellular Biochemistry, 2003, 88, 128-137.	2.6	44
25	The anti-cancer drugs curaxins target spatial genome organization. Nature Communications, 2019, 10, 1441.	12.8	44
26	FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral Latency. Journal of Biological Chemistry, 2015, 290, 27297-27310.	3.4	43
27	Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells. Oncotarget, 2017, 8, 20525-20542.	1.8	42
28	Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro-Oncology, 2017, 19, now141.	1.2	41
29	Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Research, 2003, 63, 2905-12.	0.9	41
30	Inhibition of Encephalomyocarditis Virus and Poliovirus Replication by Quinacrine: Implications for the Design and Discovery of Novel Antiviral Drugs. Journal of Virology, 2010, 84, 9390-9397.	3.4	34
31	TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. ELife, 2018, 7, .	6.0	34
32	Apoptosis Inhibitor as a Suppressor of Tumor Progression: Expression of Bcl-2 Eliminates Selective Advantages for p53-Deficient Cells in the Tumor. Cancer Biology and Therapy, 2002, 1, 39-44.	3.4	30
33	Potent antileukemic activity of curaxin CBL0137 against MLLâ€rearranged leukemia. International Journal of Cancer, 2020, 146, 1902-1916.	5.1	30
34	Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation. Frontiers in Microbiology, 2017, 8, 2007.	3.5	28
35	The 3D Genome as a Target for Anticancer Therapy. Trends in Molecular Medicine, 2020, 26, 141-149.	6.7	28
36	Quinacrine inhibits the epidermal dendritic cell migration initiating T cellâ€mediated skin inflammation. European Journal of Immunology, 2007, 37, 2257-2267.	2.9	27

#	Article	IF	Citations
37	Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate, 2007, 67, 1801-1815.	2.3	27
38	Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. PLoS ONE, 2018, 13, e0199785.	2.5	26
39	Chromatin Stability as a Target for Cancer Treatment. BioEssays, 2019, 41, e1800141.	2.5	26
40	Small-Molecule Inhibitor Which Reactivates p53 in Human T-Cell Leukemia Virus Type 1-Transformed Cells. Journal of Virology, 2008, 82, 8537-8547.	3.4	23
41	Inhibition of the FACT Complex Reduces Transcription from the Human Cytomegalovirus Major Immediate Early Promoter in Models of Lytic and Latent Replication. Journal of Virology, 2016, 90, 4249-4253.	3.4	21
42	Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Reports, 2021, 35, 108994.	6.4	21
43	Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Cell Cycle, 2009, 8, 4155-4167.	2.6	20
44	Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas. Cancer Research, 2016, 76, 6620-6630.	0.9	20
45	Histone chaperone FACT is essential to overcome replication stress in mammalian cells. Oncogene, 2020, 39, 5124-5137.	5.9	17
46	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. Clinical Cancer Research, 2021, 27, 4338-4352.	7.0	14
47	Novel synthetic cyclic integrin Î±vÎ²3 binding peptide ALOS4: antitumor activity in mouse melanoma models. Oncotarget, 2016, 7, 63549-63560.	1.8	13
48	Prognostic value of histone chaperone FACT subunits expression in breast cancer. Breast Cancer: Targets and Therapy, 2017, Volume 9, 301-311.	1.8	12
49	Small-Molecule Xenomycins Inhibit All Stages of the Plasmodium Life Cycle. Antimicrobial Agents and Chemotherapy, 2015, 59, 1427-1434.	3.2	11
50	Prevention of Colorectal Carcinogenesis by DNA-Binding Small-Molecule Curaxin CBL0137 Involves Suppression of Wnt Signaling. Cancer Prevention Research, 2020, 13, 53-64.	1.5	10
51	Prevention of Chromatin Destabilization by FACT Is Crucial for Malignant Transformation. IScience, 2020, 23, 101177.	4.1	10
52	Histone chaperone FACT and curaxins: effects on genome structure and function. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.8	10
53	Stimulation of an anti-tumor immune response with â€œchromatin-damagingâ€•therapy. Cancer Immunology, Immunotherapy, 2021, 70, 2073-2086.	4.2	8
54	Alkaloid-rich fraction of Ervatamia coronaria sensitizes colorectal cancer through modulating AMPK and mTOR signalling pathways. Journal of Ethnopharmacology, 2022, 283, 114666.	4.1	8

#	Article	IF	Citations
55	The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. Frontiers in Oncology, 0, 12, .	2.8	8
56	Influence of DNA-binding compounds with cancer preventive activity on the mechanisms of gene expression regulation. Uspehi Molekularnoj Onkologii, 2019, 5, 41-63.	0.3	6
57	FACT maintains nucleosomes during transcription and stem cell viability in adult mice. EMBO Reports, 2022, 23, e53684.	4.5	6
58	Curaxin CBL0137 has the potential to reverse HIVâ€1 latency. Journal of Medical Virology, 2019, 91, 1571-1576.	5.0	4
59	ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin. Cell Cycle, 2016, 15, 455-470.	2.6	2
60	Can aggressive cancers be identified by the â€œaggressivenessâ€•of their chromatin?. BioEssays, 2022, , 2100212.	2.5	2
61	A Translational Hepatic Artery Infusion (HAI) Model for Hepatocellular Carcinoma in Woodchucks. Journal of Surgical Research, 2020, 251, 126-136.	1.6	1
62	Prevention of Chromatin Destabilization by FACT Is Crucial for Malignant Transformation. SSRN Electronic Journal, 0, , .	0.4	1
63	Curaxin Cbl0137 Demonstrates Significant Antitumor Activity Against Fact-Positive Patient-Derived Pancreatic Ductal Adenocarcinoma. Annals of Oncology, 2013, 24, iv49.	1.2	0
64	Abstract PR09: MYCN and is a therapeutic target in neuroblastoma. , 2015, , .		0
65	Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells. Blood, 2015, 126, 1391-1391.	1.4	0
66	Targeted Modulation of Interferon Response-Related Genes with IFN-Alpha/Lambda Inhibition. International Journal of Molecular Sciences, 2022, 23, 7248.	4.1	0